Filter

1 - 10 of 99 Results

  • CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage

    Quick Insights

    Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but federal spending will also rise by some unknown amount since CMS hasn’t disclosed the projected cost.

  • Are Health Insurance Companies the Reason for Our Health System’s Ills? 

    Perspective

    In this JAMA Health Forum column, KFF's Larry Levitt examines the criticism that health insurance companies are facing from political leaders, and explores the industry's role in both causing and addressing some of the health systems' biggest problems, including rising costs and prior authorization review.

  • A Preview of the Role Health Care May Play in the 2026 Election

    Issue Brief

    Ahead of the 2026 midterm elections, this KFF issue brief examines the role health care has played in previous elections and what that may suggest about its potential role in 2026. KFF polls have consistently found that the cost of health care is an important part of voters’ economic concerns.

  • Public Opinion on Prescription Drugs and Their Prices

    Poll Finding

    This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.

  • Eight Trends Shaping 2026 Health Care Costs

    Other Post

    A new Peterson-KFF policy explainer lays out the health care trends shaping the 2026 policy debates, including rising premiums, spending on prescription drugs, health care price transparency and consolidation, artificial intelligence in health care, Medicaid funding cuts and other key program changes.

  • Key Facts About Medicare Drug Price Negotiation

    Issue Brief

    Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.

  • Examining the Potential Impact of Medicare’s New WISeR Model

    Issue Brief

    On January 1, 2026, the Center for Medicare & Medicaid Innovation (CMMI) launched the Wasteful and Inappropriate Service Reduction (WISeR) Model that establishes new prior authorization requirements in traditional Medicare. This analysis explores the potential impact of the WISeR model by examining recent spending and utilization trends in traditional Medicare for services selected for prior authorization requirements in the six model states (Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington).